Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Use of Human Hybridoma Technology To Isolate Human Monoclonal Antibodies.

Literature DB >> 26104564

Use of Human Hybridoma Technology To Isolate Human Monoclonal Antibodies.

Abstract

The human hybridoma technique offers an important approach for isolation of human monoclonal antibodies. A diversity of approaches can be used with varying success. Recent technical advances in expanding the starting number of human antigen-specific B cells, improving fusion efficiency, and isolating new myeloma partners and new cell cloning methods have enabled the development of protocols that make the isolation of human monoclonal antibodies from blood samples feasible. Undoubtedly, additional innovations that could improve efficiency are possible.

Entities: CellLine Chemical Disease Gene Species

Mesh：

Substances：

Year: 2015 PMID： 26104564 PMCID： PMC8162739 DOI： 10.1128/microbiolspec.AID-0027-2014

Source DB: PubMed Journal: Microbiol Spectr ISSN： 2165-0497

94 in total

1. Establishment of a tetraploid, immunoglobulin-producing cell line from the hybridization of two human lymphocyte lines.

Authors: A D Bloom; F T Nakamura
Journal: Proc Natl Acad Sci U S A Date: 1974-07 Impact factor: 11.205

2. Isolation and characterization of a human monoclonal antibody which reacts with breast and colorectal carcinoma.

Authors: N I Goldstein; R Nagle; H Villar; E Hersh; P B Fisher
Journal: Anticancer Res Date: 1990 Nov-Dec Impact factor: 2.480

3. Selective electrofusion of conjugated cells in flow.

Authors: T C Bakker Schut; Y M Kraan; W Barlag; L de Leij; B G de Grooth; J Greve
Journal: Biophys J Date: 1993-08 Impact factor: 4.033

4. High efficiency creation of human monoclonal antibody-producing hybridomas.

Authors: Scott K Dessain; Sharad P Adekar; Jennifer B Stevens; Katherine A Carpenter; Maria L Skorski; Barry L Barnoski; Richard A Goldsby; Robert A Weinberg
Journal: J Immunol Methods Date: 2004-08 Impact factor: 2.303

5. An optimized electrofusion-based protocol for generating virus-specific human monoclonal antibodies.

Authors: Xiaocong Yu; Patricia A McGraw; Frances S House; James E Crowe
Journal: J Immunol Methods Date: 2008-05-05 Impact factor: 2.303

6. The construction and use of a human-mouse myeloma analogue suitable for the routine production of hybridomas secreting human monoclonal antibodies.

Authors: M R Posner; H Elboim; D Santos
Journal: Hybridoma Date: 1987-12

7. Cloning of human hybridoma, myeloma and lymphoma cell lines using enriched human monocytes as feeder layer.

Authors: T Brodin; L Olsson; H O Sjögren
Journal: J Immunol Methods Date: 1983-05-27 Impact factor: 2.303

8. A human myeloma cell line that does not express immunoglobulin but yields a high frequency of antibody-secreting hybridomas.

Authors: J W Pickering; F B Gelder
Journal: J Immunol Date: 1982-07 Impact factor: 5.422

9. Idiotype variant cell populations in patients with B cell lymphoma.

Authors: W L Carroll; J N Lowder; R Streifer; R Warnke; S Levy; R Levy
Journal: J Exp Med Date: 1986-11-01 Impact factor: 14.307

10. Human hybridomas from patients with malignant disease.

Authors: K Sikora; T Alderson; J Ellis; J Phillips; J Watson
Journal: Br J Cancer Date: 1983-01 Impact factor: 7.640

35 in total

1. The identification of a novel antibody for CD133 using human antibody phage display.

Authors: Paige M Glumac; Colleen L Forster; Hong Zhou; Paari Murugan; Shilpa Gupta; Aaron M LeBeau
Journal: Prostate Date: 2018-05-22 Impact factor: 4.104

Review 2. Considerations for the Design of Antibody-Based Therapeutics.

Authors: Dennis R Goulet; William M Atkins
Journal: J Pharm Sci Date: 2019-06-04 Impact factor: 3.534

Review 3. Principles of Broad and Potent Antiviral Human Antibodies: Insights for Vaccine Design.

Authors: James E Crowe
Journal: Cell Host Microbe Date: 2017-08-09 Impact factor: 21.023

4. Potent neutralization of Rift Valley fever virus by human monoclonal antibodies through fusion inhibition.

Authors: Nathaniel S Chapman; Haiyan Zhao; Nurgun Kose; Jonna B Westover; Birte Kalveram; Robin Bombardi; Jessica Rodriguez; Rachel Sutton; Joseph Genualdi; A Desiree LaBeaud; Francis M Mutuku; Phillip R Pittman; Alexander N Freiberg; Brian B Gowen; Daved H Fremont; James E Crowe
Journal: Proc Natl Acad Sci U S A Date: 2021-04-06 Impact factor: 11.205

5. Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein.

Authors: Jarrod J Mousa; Marion F Sauer; Alexander M Sevy; Jessica A Finn; John T Bates; Gabriela Alvarado; Hannah G King; Leah B Loerinc; Rachel H Fong; Benjamin J Doranz; Bruno E Correia; Oleksandr Kalyuzhniy; Xiaolin Wen; Theodore S Jardetzky; William R Schief; Melanie D Ohi; Jens Meiler; James E Crowe
Journal: Proc Natl Acad Sci U S A Date: 2016-10-17 Impact factor: 11.205